BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SBFM catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:738e352d10bddeacdb05@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SBFM P2 readout (est.): A Study to Explore the Therapeutic Effect o
 f HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in 
 Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
DESCRIPTION:A Study to Explore the Therapeutic Effect of HEC585 on Delaying
  Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosin
 g Interstitial Lung Disease (PF-ILD) Patients\nNCT05139719 | PHASE2 | RECR
 UITING | sponsor: Sunshine Lake Pharma Co.\, Ltd.\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nTicker SBFM (confidence 0.6)\nSource: https:/
 /clinicaltrials.gov/study/NCT05139719\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05139719
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a9ff61a683325cd1a461@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:SBFM P3 readout (est.): A Study to Evaluate the Efficacy and Safety
  of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of 608 in Adult Sub
 jects With Active Ankylosing Spondylitis(AS)\nNCT07261644 | PHASE3 | RECRU
 ITING | sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co.\, Ltd.\nPr
 imary completion date (ESTIMATED)\; top-line results usually follow later.
 \nTicker SBFM (confidence 0.6)\nSource: https://clinicaltrials.gov/study/N
 CT07261644\nScheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07261644
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:199f0be1f1344fb09b7c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:SBFM P3 readout (est.): Efficacy and Safety Study of 610 in Patient
 s With Severe Asthma
DESCRIPTION:Efficacy and Safety Study of 610 in Patients With Severe Asthma
 \nNCT06323213 | PHASE3 | RECRUITING | sponsor: Sunshine Guojian Pharmaceut
 ical (Shanghai) Co.\, Ltd.\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nDate precision: month (shown on the first 
 day)\nTicker SBFM (confidence 0.6)\nSource: https://clinicaltrials.gov/stu
 dy/NCT06323213\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06323213
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4e9e8bce9a4fb2f6855c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:SBFM P2 readout (est.): A Phase IIb Study of 610 in Participants Wi
 th Severe Eosinophilic Asthma
DESCRIPTION:A Phase IIb Study of 610 in Participants With Severe Eosinophil
 ic Asthma\nNCT06680947 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sunshin
 e Guojian Pharmaceutical (Shanghai) Co.\, Ltd.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nTicker SBFM (confidence 0.6)\nSource: https://cl
 inicaltrials.gov/study/NCT06680947\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06680947
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:780416734ca235b9a390@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260429
DTEND;VALUE=DATE:20260430
SUMMARY:SBFM APPROVAL: LANGLARA
DESCRIPTION:Approved 2026-04-29: LANGLARA (BLA761412 ORIG1)\nConfidence: co
 nfirmed\nTicker SBFM (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761412\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761412
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
